PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Negative revenue growth while AVXL stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-57.23%
Negative gross profit growth while AVXL is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
5.53%
EBIT growth 1.25-1.5x AVXL's 4.81%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
5.53%
Operating income growth 1.25-1.5x AVXL's 4.81%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
5.62%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
13.79%
EPS growth of 13.79% while AVXL is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
13.79%
Diluted EPS growth of 13.79% while AVXL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
10.10%
Share count expansion well above AVXL's 6.69%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.10%
Diluted share count expanding well above AVXL's 6.69%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth above 1.5x AVXL's 7.04%. David Dodd would confirm a clear edge in underlying cash generation.
17.73%
FCF growth above 1.5x AVXL's 7.04%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
94.36%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
80.21%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-551.14%
Negative 10Y net income/share CAGR while AVXL is at 62.08%. Joel Greenblatt sees a major red flag in long-term profit erosion.
94.20%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
81.22%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
1992.70%
10Y equity/share CAGR above 1.5x AVXL's 665.89%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-67.70%
Negative 5Y equity/share growth while AVXL is at 301.92%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-15.48%
Negative 3Y equity/share growth while AVXL is at 119.01%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Asset growth well under 50% of AVXL's 53.82%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.36%
Under 50% of AVXL's 53.47%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-16.56%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-15.08%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.47%
We cut SG&A while AVXL invests at 51.89%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.